{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:44:25Z","timestamp":1793144665150,"version":"4.5.0"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:sec>\n                    <jats:title>\u00a0<\/jats:title>\n                    <jats:p>\n                      This study aimed to evaluate the synergistic effect and safety of enarodustat combined with oral iron supplementation in the treatment of iron-deficient non-dialysis-dependent chronic kidney disease (NDD-CKD) patients with anemia. This single-center retrospective cohort study enrolled 120 iron-deficient NDD-CKD patients with anemia who had not received erythropoiesis-stimulating agents or intravenous iron within the preceding month. According to the treatment protocols administered, the participants were divided into a combination therapy group (n\u2005=\u200564) and a monotherapy group (n\u2005=\u200556). The combination therapy group (n\u2005=\u200564) received enarodustat combined with ferrous succinate sustained-release tablets, while the monotherapy group (n\u2005=\u200556) received ferrous succinate sustained-release tablets alone. Patients were followed for 8 weeks to evaluate hemoglobin (Hb) levels, iron metabolism parameters, erythropoietic parameters, and adverse events. After 8 weeks of treatment, Hb levels in the combination therapy group were significantly higher than those in the monotherapy group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). The achievement rate of Hb\u2005\u2265\u2005100\u2009g\/L was 82.81% in the combination group versus 57.14% in the monotherapy group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.01); the achievement rate of Hb\u2005\u2265\u2005110\u2009g\/L was 62.50% and 44.64%, respectively (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.05). Serum ferritin, transferrin saturation, and serum iron in the combination therapy group were all significantly higher than those in the monotherapy group (all\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001). The increase in reticulocyte count and hematocrit was more pronounced in the combination group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.001), while red blood cell count showed a numerical increase without reaching statistical significance. There was no significant difference in the overall incidence of adverse events between the 2 groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&gt;\u2005.05), and no serious adverse events occurred in either group. This study indicates that enarodustat combined with oral iron supplementation may have a certain synergistic effect on iron-deficient NDD-CKD anemia compared with oral iron alone, potentially helping to improve hematological indicators and promote erythropoiesis, with an acceptable safety profile. This combined regimen may provide a preliminary reference for the management of NDD-CKD anemia.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000048101","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:01:50Z","timestamp":1775840510000},"page":"e48101","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Enarodustat combined with oral iron supplementation for iron-deficient non-dialysis-dependent chronic kidney disease anemia patients: Synergistic effects and safety"],"prefix":"10.1097","volume":"105","author":[{"given":"Ying","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-5610-5066","authenticated-orcid":false,"given":"Ganru","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260410","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","article-title":"Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017.","volume":"395","year":"2020","journal-title":"Lancet"},{"key":"R2-20260410","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/ckj\/sfac240","article-title":"Prevalence of anaemia in adults with chronic kidney disease in a representative sample of the United States population: analysis of the 1999-2018 National Health and Nutrition Examination Survey.","volume":"16","author":"Kovesdy","year":"2023","journal-title":"Clin Kidney J"},{"key":"R3-20260410","doi-asserted-by":"crossref","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","article-title":"Anemia in chronic kidney disease: from pathophysiology and current treatments, to future agents.","volume":"8","author":"Portol\u00e9s","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R4-20260410","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/s41598-022-26589-x","article-title":"A randomized trial of once daily versus twice daily dosing of oral iron in CKD.","volume":"13","author":"Sood","year":"2023","journal-title":"Sci Rep"},{"key":"R5-20260410","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/joim.13503","article-title":"Iron deficiency screening is a key issue in chronic inflammatory diseases: a call to action.","volume":"292","author":"Cacoub","year":"2022","journal-title":"J Intern Med"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"100677","DOI":"10.1016\/j.xkme.2023.100677","article-title":"Iron-deficiency anemia in CKD: a narrative review for the kidney care team.","volume":"5","author":"Hain","year":"2023","journal-title":"Kidney Med"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1681\/ASN.2019020213","article-title":"Iron deficiency in chronic kidney disease: updates on pathophysiology, diagnosis, and treatment.","volume":"31","author":"Batchelor","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000500487","article-title":"Enarodustat, conversion and maintenance therapy for anemia in hemodialysis patients: a randomized, placebo-controlled phase 2b trial followed by long-term trial.","volume":"143","author":"Akizawa","year":"2019","journal-title":"Nephron"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"173990","DOI":"10.1016\/j.ejphar.2021.173990","article-title":"JTZ-951 (enarodustat), a hypoxia-inducible factor prolyl hydroxylase inhibitor, improves iron utilization and anemia of inflammation: comparative study against recombinant erythropoietin in rat.","volume":"898","author":"Shinozaki","year":"2021","journal-title":"Eur J Pharmacol"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s40265-020-01444-3","article-title":"Enarodustat: first approval.","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/j.ekir.2021.04.037","article-title":"A phase 3 study of enarodustat in anemic patients with CKD not requiring dialysis: the SYMPHONY ND study.","volume":"6","author":"Akizawa","year":"2021","journal-title":"Kidney Int Rep"},{"key":"R12-20260410","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease.","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"R13-20260410","first-page":"40","article-title":"Clinical practice guidelines for the diagnosis and treatment of renal anemia in China.","volume":"101","year":"2021","journal-title":"Chin Med J (Engl)"},{"key":"R14-20260410","doi-asserted-by":"crossref","first-page":"e84943","DOI":"10.1371\/journal.pone.0084943","article-title":"Prevalence of anemia in chronic kidney disease in the United States.","volume":"9","author":"Stauffer","year":"2014","journal-title":"PLoS One"},{"key":"R15-20260410","doi-asserted-by":"crossref","first-page":"3035","DOI":"10.1093\/ndt\/gft338","article-title":"Anaemia management in non-dialysis chronic kidney disease (CKD) patients: a multicentre prospective study in renal clinics.","volume":"28","author":"Minutolo","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"R16-20260410","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.blre.2012.12.003","article-title":"Regulation of erythropoiesis by hypoxia-inducible factors.","volume":"27","author":"Haase","year":"2013","journal-title":"Blood Rev"},{"key":"R17-20260410","doi-asserted-by":"crossref","first-page":"105256","DOI":"10.1016\/j.phrs.2020.105256","article-title":"Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: a systematic review and meta-analysis.","volume":"163","author":"Li","year":"2021","journal-title":"Pharmacol Res"},{"key":"R18-20260410","doi-asserted-by":"crossref","first-page":"28","DOI":"10.4103\/joah.joah_63_22","article-title":"Correlation of erythroferrone and hepcidin hormones with iron status levels in patients with iron deficiency.","volume":"14","author":"Talawy","year":"2023","journal-title":"J Appl Hematol"},{"key":"R19-20260410","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41580-023-00648-1","article-title":"Mechanisms controlling cellular and systemic iron homeostasis.","volume":"25","author":"Galy","year":"2024","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"Suppl 1","key":"R20-20260410","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.2215\/CJN.01490506","article-title":"Assessing iron status: beyond serum ferritin and transferrin saturation.","volume":"1","author":"Wish","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"R21-20260410","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1813599","article-title":"Roxadustat for anemia in patients with kidney disease not receiving dialysis.","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"R22-20260410","doi-asserted-by":"crossref","first-page":"1131516","DOI":"10.3389\/fendo.2023.1131516","article-title":"Effects of hypoxia-inducible factor-prolyl hydroxylase inhibitors vs. erythropoiesis-stimulating agents on iron metabolism in non-dialysis-dependent anemic patients with CKD: a network meta-analysis.","volume":"14","author":"Yang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R23-20260410","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1080\/14656566.2025.2462181","article-title":"Real-world safety and effectiveness of roxadustat in patients with anemia of chronic kidney disease: interim results from a post-marketing surveillance study in Japan.","volume":"26","author":"Tsuruya","year":"2025","journal-title":"Expert Opin Pharmacother"},{"key":"R24-20260410","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1093\/ndt\/gfae075","article-title":"Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a clinical practice document by the European Renal Best Practice board of the European Renal Association.","volume":"39","author":"Stoumpos","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R25-20260410","doi-asserted-by":"crossref","first-page":"e0117383","DOI":"10.1371\/journal.pone.0117383","article-title":"Ferrous sulfate supplementation causes significant gastrointestinal side-effects in adults: a systematic review and meta-analysis.","volume":"10","author":"Tolkien","year":"2015","journal-title":"PLoS One"},{"key":"R26-20260410","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","article-title":"Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.","volume":"90","author":"Pergola","year":"2016","journal-title":"Kidney Int"},{"key":"R27-20260410","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1093\/ndt\/gfv302","article-title":"Randomized placebo-controlled dose-ranging and pharmacodynamics study of roxadustat (FG-4592) to treat anemia in nondialysis-dependent chronic kidney disease (NDD-CKD) patients.","volume":"30","author":"Besarab","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"R28-20260410","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.3390\/biomedicines12061191","article-title":"Anemia of chronic kidney disease \u2013 a narrative review of its pathophysiology, diagnosis, and management.","volume":"12","author":"Badura","year":"2024","journal-title":"Biomedicines"},{"key":"R29-20260410","doi-asserted-by":"crossref","first-page":"sfae205","DOI":"10.1093\/ckj\/sfae205","article-title":"Anaemia and quality of life in chronic kidney disease: a consensus document from the European anaemia of CKD alliance.","volume":"17","author":"Dasgupta","year":"2024","journal-title":"Clin Kidney J"},{"key":"R30-20260410","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease.","volume":"26","author":"Bhandari","year":"2025","journal-title":"BMC Nephrol"},{"key":"R31-20260410","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1056\/NEJMoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease.","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"R32-20260410","doi-asserted-by":"crossref","first-page":"5905","DOI":"10.1039\/D5NA00323G","article-title":"Antibody-functionalized lipid nanocarriers for RNA-based cancer gene therapy: advances and challenges in targeted delivery.","volume":"7","author":"Nabih","year":"2025","journal-title":"Nanoscale Adv"},{"key":"R33-20260410","doi-asserted-by":"crossref","first-page":"109057","DOI":"10.1016\/j.bioorg.2025.109057","article-title":"Innovative design and synthesis of dual-acting hCA IX\/CDK-2 inhibitors through hetero ring fused pyrimidine utilization for cutting-edge anticancer therapy: zein nanoparticles for in vivo lung cancer treatment.","volume":"166","author":"Abosalim","year":"2025","journal-title":"Bioorg Chem"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048101","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:21:55Z","timestamp":1785766915000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048101"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":33,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048101","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2025-11-12","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-02","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}